"The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis
Cystic fibrosis is a genetic disease that affects about 30,000 pediatric and adult patients in the United "...
Kalydeco Side Effects Center
Medical Editor: Charles Patrick Davis, MD, PhD
Kalydeco (ivacaftor) is indicated for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. There is no generic form of Kalydeco available. The most common side effects of Kalydeco include upper respiratory tract infection, headache, stomach ache, rash, diarrhea, and dizziness.
In adults and pediatric patients age 6 years and older, one 150 mg Kalydeco tablet should be given orally every 12 hours with fat-containing food. Dosage of Kalydeco should be reduced when co-administered with moderate and severe hepatic impairment. Serious side effects include liver problems. There are no adequate and well-controlled studies of Kalydeco in pregnant women. Kalydeco should be used during pregnancy only if clearly needed. Caution should be exercised when Kalydeco is administered to a nursing woman. The safety and efficacy of Kalydeco with CF patients younger than age 6 years have not been established.
Our Kalydeco Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Kalydeco FDA Prescribing Information: Side Effects
The following adverse reaction is discussed in greater detail in other sections of the label:
- Transaminase Elevations [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The overall safety profile of KALYDECO is based on pooled data from three placebo-controlled clinical trials conducted in 353 patients with CF who had a G551D mutation in the CFTR gene (Trials 1 and 2) or were homozygous for the F508del mutation (Trial 3). In addition, an 8-week crossover design trial (Trial 4) involving 39 patients with a G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, or S549R mutation in the CFTR gene was conducted. Patients treated with KALYDECO in these trials were between the ages of 6 and 57 years.
Of the 353 patients included in the pooled analyses of patients with CF who had either a G551D mutation or were homozygous for the F508del mutation in the CFTR gene, 50% of patients were female and 97% were Caucasian; 221 received KALYDECO and 132 received placebo from 16 to 48 weeks.
The proportion of patients who prematurely discontinued study drug due to adverse reactions was 2% for KALYDECO-treated patients and 5% for placebo-treated patients. Serious adverse reactions, whether considered drug-related or not by the investigators, that occurred more frequently in KALYDECO-treated patients included abdominal pain, increased hepatic enzymes, and hypoglycemia.
The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).
The incidence of adverse reactions below is based upon two double-blind, placebo-controlled, 48-week clinical trials (Trials 1 and 2) in a total of 213 patients with CF ages 6 to 53 who have a G551D mutation in the CFTR gene and who were treated with KALYDECO 150 mg orally or placebo twice daily.
Table 1 shows adverse reactions occurring in ≥ 8% of KALYDECO-treated patients with CF who have a G551D mutation in the CFTR gene that also occurred at a higher rate than in the placebo-treated patients in the two double-blind, placebo-controlled trials.
Table 1: Incidence of Adverse Drug Reactions in
≥ 8% of KALYDECO-Treated Patients with a G551D Mutation in the CFTR Gene
and Greater than Placebo in 2 Placebo-Controlled Phase 3 Clinical Trials of 48
|Adverse Reaction (Preferred Term)||Incidence: Pooled 48-week Trials|
|Headache||26 (24)||17 (16)|
|Oropharyngeal pain||24 (22)||19(18)|
|Upper respiratory tract infection||24 (22)||14 (14)|
|Nasal congestion||22 (20)||16 (15)|
|Abdominal pain||17 (16)||13(13)|
|Nasopharyngitis||16 (15)||12 (12)|
|Nausea||13 (12)||11 (11)|
|Dizziness||10 (9)||1 (1)|
Adverse reactions in the 48-week clinical trials that occurred in the KALYDECO group at a frequency of 4 to 7% where rates exceeded that in the placebo group include:
Infections and infestations: rhinitis
Musculoskeletal and connective tissue disorders: arthralgia, musculoskeletal chest pain, myalgia
Nervous system disorders: sinus headache
Skin and subcutaneous tissue disorders: acne
During 48-week placebo-controlled clinical studies, the incidence of maximum transaminase (ALT or AST) > 8, > 5 or > 3 x ULN was 2%, 3% and 6% in KALYDECO-treated patients and 2%, 2% and 8% in placebo-treated patients, respectively. Two patients (2%) on placebo and 1 patient (0.5 %) on KALYDECO permanently discontinued treatment for elevated transaminases, all > 8 x ULN. Two patients treated with KALYDECO were reported to have serious adverse reactions of elevated liver transaminases compared to none on placebo [see WARNINGS AND PRECAUTIONS].
The safety profile for the 39 patients with CF with a G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, or S549R mutation enrolled in the 8-week crossover trial (Trial 4) was similar to that observed in the 48-week placebo-controlled trials (Trials 1 and 2).
Read the entire FDA prescribing information for Kalydeco (Ivacaftor) »
Additional Kalydeco Information
- Kalydeco Drug Interactions Center: ivacaftor oral
- Kalydeco Side Effects Center
- Kalydeco FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.